Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions

Modern Pathology

Volumn 23, Issue 9, 2010, Pages 1209-1214

  Yu, Limin ^a   Harms, Paul W ^a   Pouryazdanparast, Pedram ^b   Kim, David S L ^a   Ma, Linglei ^a,c   Fullen, Douglas R ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN NODAL;

ARTICLE; CONGENITAL NEVUS; CONTROLLED STUDY; DESMOPLASTIC MELANOMA; DYSPLASTIC NEVUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MELANOMA; METASTATIC MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN DEFECT;

DYSPLASTIC NEVUS SYNDROME; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEVUS, PIGMENTED; NODAL PROTEIN; PRECANCEROUS CONDITIONS; SKIN NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 77956283187     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.101     Document Type: Article

References (36)

1. LeBoit PE, (ed). Pathology and Genetics of Skin Tumours. International Agency for Research on Cancer, World Health Organization, International Academy of Pathology, European Organization for Research on Treatment of Cancer, UniversitatsSpital Zürich. Departement Pathologie. IARC Press: Lyon, 2006, p 355.
2. Busam KJ. The use and application of special techniques in assessing melanocytic tumours. Pathology 2004;36:462-469.
3. Hocker TL, Singh MK, Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 2008;128:2575-2595.
4. Schier AF. Nodal signaling in vertebrate development. Annu Rev Cell Dev Biol 2003;19:589-621.
5. James D, Levine AJ, Besser D, et al. TGFbeta/activin/Nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 2005;132:1273-1282.
6. Vallier L, Alexander M, Pedersen RA. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci 2005; 118:4495-4509.
7. Vallier L, Reynolds D, Pedersen RA. Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. Dev Biol 2004; 275:403-421.
8. Bianco C, Adkins HB, Wechselberger C, et al. Cripto-1 activates Nodal-and ALK4-dependent and-independent signaling pathways in mammary epithelial cells. Mol Cell Biol 2002;22:2586-2597.
9. Javelaud D, Alexaki VI, Mauviel A. Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res 2008;21:123-132.
10. Krasagakis K, Kruger-Krasagakes S, Fimmel S, et al. Desensitization of melanoma cells to autocrine TGF-beta isoforms. J Cell Physiol 1999;178:179-187.
11. Rodeck U, Bossler A, Graeven U, et al. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res 1994;54:575-581.
12. Krasagakis K, Garbe C, Schrier PI, et al. Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. Anticancer Res 1994;14:2565-2571.
13. Javelaud D, Delmas V, Moller M, et al. Stable overexpression of Smad7 in human melanoma cells inhibits their tumorigenicity in vitro and in vivo. Oncogene 2005;24:7624-7629.
14. Javelaud D, Mohammad KS, McKenna CR, et al. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 2007; 67:2317-2324.
15. Topczewska JM, Postovit LM, Margaryan NV, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med 2006;12:925-932.
16. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-129.
17. Postovit LM, Margaryan NV, Seftor EA, et al. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci USA 2008;105:4329-4334.
18. Grichnik JM. Melanoma, nevogenesis, and stem cell biology. J Invest Dermatol 2008;128:2365-2380.
19. Kovalyshyn I, Braun R, Marghoob A. Congenital melanocytic naevi. Australas J Dermatol 2009;50: 231-240; quiz 41-42
20. Moustakas A. TGF-beta targets PAX3 to control melanocyte differentiation. Dev Cell 2008;15:797-799.
21. Thomas AJ, Erickson CA. The making of a melanocyte: the specification of melanoblasts from the neural crest. Pigment Cell Melanoma Res 2008;21:598-610.
22. Kawakami T, Soma Y, Kawa Y, et al. Transforming growth factor beta1 regulates melanocyte proliferation and differentiation in mouse neural crest cells via stem cell factor/KIT signaling. J Invest Dermatol 2002;118:471-478.
23. Busam KJ. Cutaneous desmoplastic melanoma. Adv Anat Pathol 2005;12:92-102.
24. Busam KJ, Zhao H, Coit DG, et al. Distinction of desmoplastic melanoma from non-desmoplastic melanoma by gene expression profiling. J Invest Dermatol 2005;124:412-418.
25. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113: 685-700.
26. Gritsman K, Zhang J, Cheng S, et al. The EGF-CFC protein one-eyed pinhead is essential for Nodal signaling. Cell 1999;97:121-132.
27. Reissmann E, Jornvall H, Blokzijl A, et al. The orphan receptor ALK7 and the Activin receptor ALK4 mediate signaling by Nodal proteins during vertebrate development. Genes Dev 2001;15:2010-2022.
28. Yan YT, Liu JJ, Luo Y, et al. Dual roles of Cripto as a ligand and coreceptor in the Nodal signaling pathway. Mol Cell Biol 2002;22:4439-4449.
29. Yeo C, Whitman M. Nodal signals to Smads through Cripto-dependent and Cripto-independent mechanisms. Mol Cell 2001;7:949-957.
30. Ben-Haim N, Lu C, Guzman-Ayala M, et al. The Nodal precursor acting via activin receptors induces mesoderm by maintaining a source of its convertases and BMP4. Dev Cell 2006;11:313-323.
31. Liguori GL, Borges AC, DAndrea D, et al. Criptoindependent Nodal signaling promotes positioning of the A-P axis in the early mouse embryo. Dev Biol 2008;315:280-289.
32. Strizzi L, Abbott DE, Salomon DS, et al. Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle 2008;7:1931-1935.
33. Strizzi L, Postovit LM, Margaryan NV, et al. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol 2009;4:67-78.
34. Harms PW, Chang C. Tomoregulin-1 (TMEFF1) inhibits Nodal signaling through direct binding to the Nodal coreceptor Cripto. Genes Dev 2003;17:2624-2629.
35. Chen C, Shen MM. Two modes by which Lefty proteins inhibit Nodal signaling. Curr Biol 2004;14: 618-624.
36. Piccolo S, Agius E, Leyns L, et al. The head inducer Cerberus is a multifunctional antagonist of Nodal, BMP and Wnt signals. Nature 1999;397:707-710.